Prelude Therapeutics, Inc. (PRLD)
5.34
-0.13
(-2.38%)
USD |
NASDAQ |
Aug 31, 09:54
Prelude Therapeutics Debt to Equity Ratio : 0.132 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.132 |
| March 31, 2026 | 0.2945 |
| December 31, 2025 | 0.2592 |
| September 30, 2025 | 0.305 |
| June 30, 2025 | 0.2363 |
| March 31, 2025 | 0.1737 |
| December 31, 2024 | 0.1371 |
| September 30, 2024 | 0.1159 |
| June 30, 2024 | 0.0999 |
| March 31, 2024 | 0.0837 |
| December 31, 2023 | 0.0712 |
| September 30, 2023 | 0.002 |
| June 30, 2023 | 0.0036 |
| March 31, 2023 | 0.0079 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.0094 |
| September 30, 2022 | 0.0064 |
| June 30, 2022 | 0.0076 |
| March 31, 2022 | 0.0086 |
| December 31, 2021 | 0.0061 |
| September 30, 2021 | 0.0069 |
| June 30, 2021 | 0.0058 |
| March 31, 2021 | 0.0063 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.0025 |
| March 31, 2020 | |
| December 31, 2019 | 0.0151 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Intellia Therapeutics, Inc. | 0.1009 |
| Twist Bioscience Corp. | 0.21 |
| Beam Therapeutics, Inc. | 0.2317 |
| Revolution Medicines, Inc. | 0.4568 |
| Sana Biotechnology, Inc. | 0.4771 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 189.36M |
| Total Liabilities (Quarterly) | 55.63M |
| Shareholders Equity (Quarterly) | 133.73M |
| Current Ratio | 4.072 |
| Net Debt Paydown Yield | 0.01% |